zurück

Ponesimod (relapsing forms of multiple sclerosis (RMS))

Subject:

  • Active Substance: Ponesimod
  • Name: Ponvory®
  • Therapeutic area: Multiple sclerosis
  • Pharmaceutical company: Janssen-Cilag GmbH

Time table:

  • Start: 01.12.2021
  • Final decision by G-BA: 19.05.2022

Final decision:

  • a1) Patients with EDSS-Score ≤ 3,5: Indication for a minor additional benefit
    a2) Patients with EDSS-Score > 3,5: No additional benefit proved